PDEX vs. STIM, TTOO, DRIO, XAIR, LYRA, RCEL, DCTH, SMLR, OM, and CLPT
Should you be buying Pro-Dex stock or one of its competitors? The main competitors of Pro-Dex include Neuronetics (STIM), T2 Biosystems (TTOO), DarioHealth (DRIO), Beyond Air (XAIR), Lyra Therapeutics (LYRA), AVITA Medical (RCEL), Delcath Systems (DCTH), Semler Scientific (SMLR), Outset Medical (OM), and ClearPoint Neuro (CLPT). These companies are all part of the "medical" sector.
Pro-Dex (NASDAQ:PDEX) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.
15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 42.6% of Pro-Dex shares are owned by insiders. Comparatively, 9.8% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Neuronetics had 3 more articles in the media than Pro-Dex. MarketBeat recorded 6 mentions for Neuronetics and 3 mentions for Pro-Dex. Neuronetics' average media sentiment score of 0.75 beat Pro-Dex's score of 0.22 indicating that Neuronetics is being referred to more favorably in the news media.
Pro-Dex has a net margin of 4.13% compared to Neuronetics' net margin of -37.61%. Pro-Dex's return on equity of 6.50% beat Neuronetics' return on equity.
Pro-Dex has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Pro-Dex received 22 more outperform votes than Neuronetics when rated by MarketBeat users. However, 68.48% of users gave Neuronetics an outperform vote while only 60.91% of users gave Pro-Dex an outperform vote.
Pro-Dex has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Neuronetics has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500.
Neuronetics has a consensus price target of $8.00, suggesting a potential upside of 323.28%. Given Neuronetics' higher possible upside, analysts clearly believe Neuronetics is more favorable than Pro-Dex.
Summary
Pro-Dex beats Neuronetics on 9 of the 17 factors compared between the two stocks.
Get Pro-Dex News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
